Overview of <i>Helicobacter pylori</i> Infection, Prevalence, Risk Factors, and Its Prevention

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="1"><hr/></td></tr><tr><td class="align_left">(i) Susceptibility-guided therapy/antibiotic sensitivity testing<br/>(ii) PPI-high dose<br/>(iii) Novel antibiotics<br/>(iv) Clarithromycin avoidance, if used previously<br/>(v) Antibiotic course for 14 days<br/>(vi) Probiotics with antibiotics<br/>(vii) Vonoprazan (P-CAB) instead of PPI<br/>(viii) PCR/DNA extraction (from stool sample) for making a diagnosis<br/>(ix) Nanotechnology use</td></tr><tr class="table-tr"><td colspan="1"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Prospects in the management of <i>H. pylori</i> infection.</div>

Advanced Gut & Microbiome Research

tab3

Table 3

Table 3: Overview of <i>Helicobacter pylori</i> Infection, Prevalence, Risk Factors, and Its Prevention 

Advanced Gut & Microbiome Research

Overview of Helicobacter pylori Infection, Prevalence, Risk Factors, and Its Prevention

Table 3